Abstract: Objective To evaluate the efficacy and safety of recombinant human endostatin（Endostar）plus cisplatin perfusion chemotherapy versus cisplatin alone in the treatment of malignant pleural effusions. Methods Databases of PubMed， The Cochrane Library， Web of Science， Wanfang， CNKI， VIP were searched and randomized controlled trials（RCTs） on endostar plus cisplatin versus cisplatin alone for malignant pleural effusions from 2005 to 2015 were collected. The quality of RCTs was assessed by Cochrane handbook 50 and Metaanalysis was carried out by RevMan 5.2 software. Results A total of 15 RCTs involving 936 patients were included. Compared with the cisplatin alone group， the endostar plus cisplatin group had a higher effective rate of controlling malignant effusions（RR=1.54，95％CI：1.38-1.71，P＜0.000 01）， better improvement in quality of life（RR=1.61，95％CI：1.41-1.84，P＜0.000 01）. As for side effects， there were no significant differences between the two groups in the incidences of gastrointestinal reaction， chest pain， fever， myelosuppression， dysfunction of liver and kidney， fatigue， electrocardiographic abnormality. Conclusion Compared with cisplatin alone， endostar plus cisplatin can improve the efficacy and quality of life of patients with malignant pleural effusions without increasement of adverse reactions.